Publications
Aoki S, Inoue K, Klein S, Halvorsen S, Chen J, Matsui A, Nikmaneshi MR, Kitahara S, Hato T, Chen X, Kawakubo K, Nia HT, Chen I, Schanne DH, Mamessier E, Shigeta K, Kikuchi H, Ramjiawan RR, Schmidt TC, Iwasaki M, Yau T, Hong TS, Quaas A, Plum PS, Dima S, Popescu I, Bardeesy N, Munn LL, Borad MJ, Sassi S, Jain RK, Zhu AX, Duda DG
Placental growth factor promotes tumor desmoplasia and treatment resistance in intrahepatic cholangiocarcinoma
Gut. 2021 Jan 11:gutjnl-2020-322493.
[Citation: - ] [IF: 23.06 (JCR 2020)]
Wong JSL, Kwok GGW, Tang V, Li BCW, Leung R, Chiu J, Ma KW, She WH, Tsang J, Lo CM, Cheung TT, Yau T.
Ipilimumab and Nivolumab/Pembrolizumab in Advanced Hepatocellular Carcinoma Refractory to Prior Immune Checkpoint Inhibitors.
Journal For Immunotherapy of Cancer 2021 Feb;9(2):e001945.
[Citation: 4 ] [IF:13.75 (JCR 2020)]
Wai Lui DT, Lee CH, Tang V, Fong CHY, Lee ACH, Chiu JWY, Leung RCY, Kwok GGW, Li BCW, Cheung TT, Woo YC, Lam KSL, Yau T
Thyroid Immune-Related Adverse Events in Cancer Patients Treated with Anti-PD1/Anti-CTLA4 Immune-Checkpoint Inhibitor Combination
Endocr Pract. 2021 Feb 10:S1530-891X(21)00030-6.
[Citation: 1 ] [IF: 3.44 (JCR 2020)]
Mou H, Yang QA, Yu L, Wang T, Liu K, Shen R, Pan X, Dai Y, Wan Q, Zhou F, Qian L, Chen D, Yau T , Dong X, Wang X, Wang S.
PD-L1 expression in hepatocellular carcinoma and its correlation with clinicopathological characteristics
J Gastroenterol Hepatol. 2021 Mar 3
[Citation: - ] [IF: 4.03 (JCR 2020)]
Tsang J, Wong JSL, Kwok GGW, Li BCW, Leung R, Chiu J, Cheung TT, Yau T.
Drug Profile: Nivolumab plus Ipilimumab for Patients with Hepatocellular Carcinoma previously treated with Sorafenib
Expert Review of Gastroenterology & Hepatology 2021 Mar 5
[Citation: 2 ] [IF: 3.87 (JCR 2020)]
Dong Y, Wong JSL, Sugimura R, Lam KO, Li B, Kwok GGW, Leung R, Chiu JWY, Cheung TT, Yau T
Cancers (Basel). 2021 Apr 18;13(8):1949.
[Citation: - ] [IF: 6.64 (JCR 2020)]
Wong JS, Dong Y, Tang V, Leung T, Yeung CSY, Tai A, Law A, Shum T, Kwok GG, Li BC, Leung R, Chiu J, Ma KW, She WH, Tsang J, Cheung TT, Yau T
The Use of Cabozantinib in Advanced Hepatocellular Carcinoma in Hong Kong—A Territory-Wide Cohort Study
Cancers (Basel). 2021 Apr 21;13(9):2002.
[Citation: - ] [IF: 6.64 (JCR 2020)]
Wiedermann U, Garner-Spitzer E, Chao Y, Maglakelidze M, Bulat I, Dechaphunkul A, Arpornwirat W, Charoentum C, Yen CJ, Yau T, Tanasanvimon S, Maneechavakajorn J, Sookprasert A, Bai LY, Chou WC, Ungtrakul T, Drinić M, Tobias J, Zielinski CC, Chong L, Ede NJ, Marino MT, Good AJ.
Characterization of clinical and immunologic responses to a novel HER2/neu B-cell epitope 2 vaccine in HER2/neu overexpressing advanced gastric cancer patients – results from Phase 3 1b trial IMU.ACS.001
Clin Cancer Res. 2021 Apr 20
[Citation: - ] [IF: 12.53 (JCR 2020)]
Wong CY, Leung R, Kwok GW, Tsang J, Li B, Yau T, Chiu J.
Safety and tolerability of subcutaneous trastuzumab and intravenous pertuzumab as adjuvant treatment for HER2 positive breast cancer
Postgrad Med J. 2021 May 26. doi:10.1136/postgradmedj-2021-140319
[Citation: -] [IF: 2.40 (JCR 2020)]
Kudo M, Lim HY, Cheng AL, Chao Y, Yau T, Ogasawara S, Kurosaki M, Morimoto N, Ohkawa K, Yamashita T, Lee KH, Chen E, Siegel AB, Ryoo BY.
Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: A Subgroup Analysis of Asian Patients in the Phase 3 KEYNOTE-240 Trial
Liver Cancer. 2021 Jun;10(3):275-284
[Citation: - ] [IF: 11.74 (JCR 2020)]
Qin S, Ren Z, Feng Y, -H, Yau T, Wang B, Zhao H, Bai Y, Gu S, Li L, Hernandez S, Xu D, -Z, Mulla S, Wang Y, Shao H, Cheng A, L
Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study
Liver Cancer (In Press) 2021. doi: 10.1159/000513486
[Citation: - ] [IF: 11.74 (JCR 2020)]
Kelley RK, Sangro B, Harris W, Ikeda M, Okusaka T, Kang YK, Qin S, Tai DW, Lim HY, Yau T, Yong WP, Cheng AL, Gasbarrini A, Damian S, Bruix J, Borad M, Bendell J, Kim TY, Standifer N, He P, Makowsky M, Negro A, Kudo M, Abou-Alfa GK.
Efficacy and Tolerability of Novel Regimen of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study
J Clin Oncol. 2021 Jul 22
[Citation: - ] [IF: 44.54 (JCR2020)]
Ho Yin Chung, Shirley Chiu Wai Chan, Eva Tsz Fung Chui, Thomas Chung Cheung Yau, Chak Sing Lau
Malignancies in patients with spondyloarthritis with and without concomitant psoriasis, and the effect of disease modifying anti-rheumatic drugs
Clinical and Experimental Rheumatology (In Press)
[Citation: - ] [IF: 3.32(JCR2020)]
Tim F. Greten, Ghassan K. Abou-Alfa, Ann-Lii Cheng , Austin G. Duffy , Anthony B. El-Khoueiry, Richard S. Finn , Peter R. Galle, Lipika Goyal, Aiwu Ruth He, Ahmed O. Kaseb, Robin Kate Kelley , Riccardo Lencioni, Amaia Lujambio, Donna Mabry Hrones, David J. Pinato, Bruno Sangro, , Roberto I. Troisi Andrea Wilson Woods, Thomas Yau, Andrew X. Zhu, , Ignacio Melero
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma
Journal For Immunotherapy of Cancer (In Press)
[Citation: - ] [IF: 13.75 (JCR 2020)]
Arndt Vogel; Philippe Merle; Chris Verslype; Richard S. Finn; Andrew X. Zhu; Ann-Lii Cheng; Stephen Lam Chan; Thomas Yau; Baek-Yeol Ryoo; Jennifer Knox; Bruno Daniele; Shukui Qin; Ziwen Wei; Yanna Miteva; Usha Malhotra; Abby B. Siegel; Masatoshi Kudo
Baseline Liver Function and Outcomes in Patients With Unresectable Hepatocellular Carcinoma Enrolled in a Randomized, Double-Blind, Phase 3 Study (KEYNOTE-240)
Therapeutic Advances in Medical Oncology (In Press)
[Citation: - ] [IF: 8.17 (JCR 2020)]
Li BC, Chiu J, Shing K, Kwok GG, Tang V, Leung R, Ma KW, She WH, Tsang J, Chan A, Cheung TT.
The Outcomes of Systemic Treatment in Recurrent Hepatocellular Carcinomas Following Liver Transplants.
Advances in Therapy. 2021 Jun 1:1-1.
[Citation: - ] [IF: 3.85 (JCR 2020)]
Yap YS, Chiu J, Ito Y, Ishikawa T, Aruga T, Kim SJ, Toyama T, Saeki T, Saito M, Gounaris I, Su F, Ji Y, Han Y, Gazdoiu M, Masuda N.
Ribociclib, a CDK 4/6 inhibitor, plus endocrine therapy in Asian women with advanced breast cancer
Cancer Sci. 2020 Sep;111(9):3313-3326. doi: 10.1111/cas.14554. Epub 2020 Jul 28.
[Citation: -] [IF: 6.72 (JCR 2020)]
Dawood S, Chiu JW, Huang CS, Nag S, Sookprasert A, Yap YS, Md Yusof M.
Palbociclib and beyond for the treatment of HR + HER2- metastatic breast cancer: an Asian-Pacific perspective and practical management guide on the use of CDK4/6 inhibitors.
Curr Med Res Opin. 2020 Aug;36(8):1363-1373. doi: 10.1080/03007995.2020.1783646. Epub 2020 Jul 2.PMID: 32544344
[Citation: -] [IF: 2.58 (JCR 2020)]
Shing K, Kwok G, Chiu J, Cheung TT, Yau T.
Editorial: Sorafenib plus Doxorubicin in Advanced Hepatocellular Carcinoma Patients: Hope or Hype?
Annals of Translational Medicine 2020;8(24):1695
[Citation: -] [IF: 3.93 (JCR 2020)]
Xu J, Xu RH, Qin S, Pan H, Bai Y, Chi Y, Wang L, Bi F, Cheng Y, Liu T, Ma D, Shen L, Ba Y, Liang J, Wang X, Yau TCC, Ma BB, Yeh KH, Lin JK, Kappeler C, Shapiro J, Kalmus J, Li J.
Regorafenib in Chinese patients with metastatic colorectal cancer: Subgroup analysis of the phase 3 CONCUR trial
J Gastroenterol Hepatol. 2020 Jan 3
[Citation: 4 ] [IF: 4.03 (JCR 2020)]
Finn RS, Ryoo BY, Merle P, Kudo M, Bouattour M, Lim HY, Breder V, Edeline J, Chao Y, Ogasawara S, Yau T, Garrido M, Chan SL, Knox J, Daniele B, Ebbinghaus SW, Chen E, Siegel AB, Zhu AX, Cheng AL
KEYNOTE-240 investigators. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase 3 trial.
J Clin Oncol. 2020 Jan 20;38(3):193-202.
[Citation: 58 ] [IF: 44.54 (JCR 2020)]
Chiu DK, Yuen VW, Wing-Sum Cheu J, Wei LL, Ting V, Fehlings M, Sumatoh H, Nardin A, Newell EW, Oi-Lin Ng I, Yau TC, Wong CM, Wong CC.
Hepatocellular Carcinoma Cells Upregulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice.
Gastroenterology 2020 Apr 7;S0016-5085(20)30461-3.
[Citation: 20 ] [IF: 22.68 (JCR 2020)]
Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Kudo M, Breder V, Merle P, Kaseb AO, Li D, Verret W, Xu DZ, Hernandez S, Liu J, Huang C, Mulla S, Wang Y, Lim HY, Zhu AX, Cheng AL, IMbrave150 Investigators.
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.
N Engl J Med. 2020 May 14;382(20):1894-1905.
[Citation: 826 ] [IF: 91.25 (JCR 2020)]
Kelley RK, Mollon P, Blanc JF, Daniele B, Yau T, Cheng AL, Valcheva V, Marteau F, Guerra I, Abou-Alfa GK.
Comparative efficacy of cabozantinib and regorafenib for advanced hepatocellular carcinoma.
Adv Ther. 2020 May 18.
[Citation: 11 ] [IF: 3.85 (JCR 2020)]
Robin Kate Kelley, Saswati Hazra, Jennifer W. Oliver, Ann-Lii Cheng, Thomas Yau, Lorenza Rimassa5.
Cabozantinib in combination with atezolizumab as first-line therapy for advanced hepatocellular carcinoma: COSMIC-312 phase 3 study design.
Future Oncology. 2020 Jun 3
[Citation: 17 ] [IF: 3.40 (JCR 2020)]
Zhang BZ, Hu YF, Chen LL, Yau T, Tong YG, Hu JC, Cai JP, Chan KH, Dou Y, Deng J, Wang XL, Hung IF, To KK, Yuen KY, Huang JD.
Mining of Epitopes on Spike Protein of SARS-CoV-2 from COVID-19 Patients.
Cell Research 2020 Jul 1:1-3. (Letter)
[Citation: 53 ] [IF: 25.62 (JCR 2020)]
Kelley RK, Meyer T, Rimassa L, Merle P, Park JW, Yau T, Chan SL, Blanc JF, Tam VC, Tran A, Dadduzio V, Markby DW, Kaldate R, Cheng AL, El-Khoueiry AB, Abou-Alfa GK.
Serum alpha-fetoprotein levels and clinical outcome in the phase 3 CELESTIAL study of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma.
Clin Cancer Res 2020 Jul 7
[Citation: 8 ] [IF: 12.53 (JCR 2020)]
Dong Y, Liu TH, Yau T, Hsu C.
Novel systemic therapy for hepatocellular carcinoma (HCC).
Hepatic international 2020 Jul 13.
[Citation: 6 ] [IF: 6.05 (JCR 2020)]
Saura C, Oliveira M, Feng YH, Dai MS, Chen SW, Hurvitz SA, Kim SB, Moy B, Delaloge S, Gradishar W, Masuda N, Palacova M, Trudeau ME, Mattson J, Yap YS, Hou MF, De Laurentiis M, Yeh YM, Chang HT, Yau T, Wildiers H, Haley B, Fagnani D, Lu YS, Crown J, Lin J, Takahashi M, Takano T, Yamaguchi M, Fujii T, Yao B, Bebchuk J, Keyvanjah K, Bryce R, Brufsky A;NALA Investigators
Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial.
J Clin Oncol. 2020 Jul 17:JCO2000147
[Citation: 88 ] [IF: 44.54 (JCR 2020)]
Sangro B, Melero I, Wadhawan S, Finn RS, Abou-Alfa GK, Cheng AL, Yau T, Furuse J, Park JW, Boyd Z, Tang HT, Shen Y, Tschaika M, Neely J, El-Khoueiry A.
Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma.
Journal of Hepatology, Volume 73, Issue 6, 2020, Pages 1460-1469, ISSN 0168-8278
[Citation: 36 ] [IF: 25.08 (JCR 2020)]
Bao-Zhong Zhang, Hin Chu, Shuo Han, Huiping Shuai, Jian Deng, Ye-fan Hu, Hua-rui Gong, Andrew Chak-Yiu Lee, Zijiao Zou, Thomas Yau, Wutian Wu, Ivan Fan-Ngai Hung, Jasper Fuk-Woo Chan, Kwok-Yung Yuen, Jian-Dong Huang,
SARS-CoV-2 infects human neural progenitor cells and brain organoids.
Cell Research 2020 Aug 4. (Letter)
[Citation: 87 ] [IF: 25.62 (JCR 2020)]
Robin Kate Kelley, Baek-Yeol Ryoo, Philippe Merle, Joong-Won Park,Luigi Bolondi, Stephen L. Chan, Ho Yeong Lim, Ari Baron,8 Francis Parnis, Jennifer Knox, Stephane Cattan, Thomas Yau , Julie C. Lougheed, Steven Milwee, Anthony B. El-Khoueiry, Ann-Lii Cheng, Tim Meyer, Ghassan K.
Abou-Alfa
Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: A subgroup analysis of the phase 3 CELESTIAL trial.
ESMO OPEN .2020 Aug;5(4):e000714.
[Citation: 8 ] [IF: 6.54 (JCR 2020)]
Thomas Yau, Yoon-Koo Kang, Tae-You Kim, Anthony B. El-Khoueiry, Armando Santoro, Bruno Sangro, Ignacio Melero, Masatoshi Kudo, Ming-Mo Hou, Ana Matilla, Francesco Tovoli, Jennifer J. Knox, Aiwu Ruth He, Bassel El-Rayes, Mirelis Acosta-Rivera,Ho-Yeong Lim, Jaclyn Neely, Yun Shen, Carlos Baccan, Chiun Hsu.
Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the CheckMate 040 randomized clinical trial
JAMA Oncology 2020 Oct 1
[Citation: 101 ] [IF: 31.78 (JCR 2020)]
Ryoo BY, Merle P, Kulkarni AS, Cheng AL, Bouattour M, Lim HY, Breder V, Edeline J, Chao Y, Ogasawara S, Yau T, Garrido M, Chan SL, Daniele B, Norquist JM, Chen E, Siegel AB, Zhu AX, Finn RS, Kudo M.
Health-Related Quality-of-Life Impact of Pembrolizumab Versus Best Supportive Care in Previously Systemically Treated Patients With Advanced Hepatocellular Carcinoma: KEYNOTE-240.
Cancer. 2020 Nov 24.
[Citation: 3 ] [IF: 5.24 (JCR 2020)]
Chui AMN, Yau TCC, Cheung TT.
An overview in management of hepatocellular carcinoma in Hong Kong using the Hong Kong Liver Cancer (HKLC) staging system.
Glob Health Med. 2020 Oct 31;2(5):312-318.
[Citation: - ] [IF: NA]
Saura C, Oliveira M, Kim SB, Yau T, Takano T, Brufsky A.
Reply to T.J.A. Dekker, D.C. Mo et al, and A. Seidman et al.
J Clin Oncol. 2020 Dec 17:JCO2002963 (Letter)
[Citation: - ] [IF: 44.54 (JCR 2020)]
Kim SB, Do IG, Tsang J, Kim TY, Yap YS, Cornelio G, Gong G, Paik S, Lee S, Ng TY, Park S, Oh HS, Chiu J, Sohn J, Lee M, Choi YJ, Lee EM, Park KH, Nathaniel C, Ro
BioPATH: A Biomarker Study in Asian Patients with HER2+ Advanced Breast Cancer Treated with Lapatinib and Other Anti-HER2 Therapy.
J.Cancer Res Treat. 2019 Oct;51(4):1527-1539. doi: 10.4143/crt.2018.598. Epub 2019 Jun 4.PMID: 31163957
[Citation: 1 ] [IF: 3.76 (JCR 2019)]
Iwata H, Masuda N, Kim SB, Inoue K, Rai Y, Fujita T, Chiu J, Ohtani S, Takahashi M, Miyaki T, Lu YS, Xu B, Yap YS, Bustam A, Yao B, Zhang B, Bryce R, Chan A.
Future Oncol. 2019 Jul;15(21):2489-2501. doi: 10.2217/fon-2019-0143. Epub 2019 May 29.PMID: 31140297 Clinical Trial.
[Citation: 5 ] [IF: 2.66 (JCR 2019)]
Yeo W, Ueno T, Lin CH, Liu Q, Lee KH, Leung R, Naito Y, Park YH, Im SA, Li H, Yap YS, Lu YS; Asian Breast Cancer Cooperative Group
Treating HR+/HER2- breast cancer in premenopausal Asian women: Asian Breast Cancer Cooperative Group 2019 Consensus and position on ovarian suppression.
Breast Cancer Res Treat. 2019 Oct;177(3):549-559. doi: 10.1007/s10549-019-05318-5. Epub 2019 Jul 4.PMID: 31270763 Review.
[Citation: 15 ] [IF: 3.83 (JCR 2019)]
Lin CH, Yap YS, Lee KH, Im SA, Naito Y, Yeo W, Ueno T, Kwong A, Li H, Huang SM, Leung R, Han W, Tan B, Hu FC, Huang CS, Cheng AL, Lu YS; Asian Breast Cancer Cooperative Group.
Contrasting Epidemiology and Clinicopathology of Female Breast Cancer in Asians vs the US Population.
J Natl Cancer Inst. 2019 Dec 1;111(12):1298-1306. doi: 10.1093/jnci/djz090.PMID: 31093668
[Citation: 31 ] [IF: 13.76 (JCR 2011)]
El Dika I, Lim HY, Yong WP, Lin CC, Yoon JH, Modiano M, Freilich B, Choi HJ, Chao TY, Kelley RK, Brown J, Knox J, Ryoo BY, Yau T, Abou-Alfa GK. An Open-Label, Multicenter, Phase I, Dose Escalation Study with Phase II Expansion Cohort to Determine the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Intravenous TKM-080301 in Subjects with Advanced Hepatocellular Carcinoma.
Oncologist 2019; 24(6):747-e218.
[Citation: 30 ] [IF: 5.03 (JCR 2019)]
Chiu JW, Leung R, Tang V, Cheuk WY, Lo J, Kwok GW, Wong H, Suen D, Cheung P, Wong TT, Yau T, Kwong A.
Changing pattern of recurrences in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy in the era of dual anti-HER2 therapy.
Postgrad Med J 2019; 95(1121):155-161.
[Citation: 1 ] [IF: 1.91 (JCR 2019)]
Yau T, Hsu C, Kim TY, Choo SP, Kang YK, Hou MM, Numata K, Yeo W, Chopra A, Ikeda M, Kuromatsu R, Moriguchi M, Chao Y, Zhao H,erson J, Cruz CD, Kudo M.
Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis.
J Hepatol 2019; 71(3):543-552.
[Citation: 81 ] [IF: 20.58 (JCR 2019)]
Ng L, Kwan V, Chow A, Yau TC, Poon RT, Pang R, Law WL.
Overexpression of Pin1 and rho signaling partners correlates with metastatic behavior and poor recurrence-free survival of hepatocellular carcinoma patients.
BMC Cancer 2019; 19(1):713.
[Citation: 4 ] [IF: 3.15 (JCR 2019)]
Cheung TT, Chok KS, Chan AC, Tsang SH, Dai WC, Yau TC, Kwong A, Lo CM.
Survival analysis of breast cancer liver metastasis treated by hepatectomy: A propensity score analysis for Chinese women in Hong Kong.
Hepatobiliary Pancreat Dis Int 2019; 18(5):452-457.
[Citation: 3 ] [IF: 2.43 (JCR 2019)]
Kim RD, Sarker D, Meyer T, Yau T, Macarulla T, Park JW, Choo SP, Hollebecque A, Sung MW, Lim HY, Mazzaferro V, Trojan J, Zhu AX, Yoon JH, Sharma S, Lin ZZ, Chan SL, Faivre S, Feun LG, Yen CJ, Dufour JF, Palmer DH, Llovet JM, Manoogian M, Tugnait M, Strans.
First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant Fibroblast Growth Factor 19 Signaling as a Driver Event in Hepatocellular Carcinoma.
Cancer Discov 2019 Dec;9(12):1696-1707.
[Citation: 55 ] [IF: 29.50 (JCR 2019)]
Qin S, Chan SL, Sukeepaisarnjaroen W, Han G, Choo SP, Sriuranpong V, Pan H, Yau T, Guo Y, Chen M, Ren Z, Xu J, Yen CJ, Lin ZZ, Manenti L, Gu Y, Sun Y, Tiedt R, Hao L, Song W, Tanwandee T.
A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma
Therapeutic Advances in Medical Oncology. 2019 Dec 11;11
[Citation: 19 ] [IF: 6.85 (JCR 2019)]
Chiu JW, Krzyzanowska MK, Serra S, Knox JJ, Dhani NC, Mackay H, Hedley D, Moore M, Liu G, Burkes RL, Brezden-Masley C, Roehrl MH, Craddock KJ, Tsao MS, Zhang T, Yu C, Kamel-Reid S, Siu LL, Bedard PL, Chen EX.
Molecular Profiling of Patients With Advanced Colorectal Cancer: Princess Margaret Cancer Centre Experience.
Clin Colorectal Cancer. 2018 Mar;17(1):73-79. doi: 10.1016/j.clcc.2017.10.010. Epub 2017 Oct 23.PMID: 29128266
[Citation: 15] [IF: 3.18 (JCR 2018)]
Chiu JW, Hotte SJ, Kollmannsberger CK, Renouf DJ, Cescon DW, Hedley D, Chow S, Moscow J, Chen Z, Perry M, Diaz-Padilla I, Tan D, Hirte H, McWhirter E, Chen H, Siu LL, Bedard PL.
A phase I trial of ANG1/2-Tie2 inhibitor trebaninib (AMG386) and temsirolimus in advanced solid tumors (PJC008/NCI♯9041).
Invest New Drugs. 2016 Feb;34(1):104-11. doi: 10.1007/s10637-015-0313-8. Epub 2015 Dec 19.PMID: 26686201 Clinical Trial.
[Citation: 14 ] [IF: 2.66 (JCR 2018)]
Cheung TT, Kwok PC, Chan S, Cheung CC, Lee AS, Lee V, Cheng HC, Chia NH, Chong CCN, Lai TW, Law ALY, Luk MY, Tong CC, Yau TCC
Hong Kong Consensus Statements for the Management of Unresectable Hepatocellular Carcinoma.
Liver Cancer 2018; 7(1):40-54.
[Citation: 14 ] [IF: 5.94 (JCR 2018)]
Ng L, Chow AKM, Man JHW, Yau TCC, Wan TMH, Iyer DN, Kwan VHT, Poon RTP, Pang RWC, Law WL.
Suppression of Slit3 induces tumor proliferation and chemoresistance in hepatocellular carcinoma through activation of GSK3beta/beta-catenin pathway.
BMC Cancer 2018; 18(1):621.
[Citation: 13 ] [IF: 2.93 (JCR 2018)]
Lim HY, Merle P, Weiss KH, Yau T, Ross P, Mazzaferro V, Blanc JF, Ma YT, Yen CJ, Kocsis J, Choo SP, Sukeepaisarnjaroen W, Gerolami R, Dufour JF, Gane EJ, Ryoo BY, Peck-Radosavljevic M, Dao T, Yeo W, Lamlertthon W, Thongsawat S, Teufel M, Roth K, Reis D, C.
Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with RAS-Mutated Hepatocellular Carcinoma.
lin Cancer Res 2018; 24(19):4650-4661
[Citation: 35 ] [IF: 8.91 (JCR 2018)]
Cheng AL, Cornelio G, Shen L, Price T, Yang TS, Chung IJ, Dai GH, Lin JK, Sharma A, Yeh KH, Ma B, Zaatar A, Guan Z, Masood N, Srimuninnimit V, Yau T, Gibbs P, Wang X, Doval DC, Oh ST, Shim BY, Gorospe C, Wang HM, Sirachainan E, Hill A, Suh KW, Beier F, Ch.
Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study.
Clin Colorectal Cancer 2017; 16(2):e73-e88.
[Citation: 11 ] [IF: 3.86 (JCR 2017)]
Yau TCC, Lencioni R, Sukeepaisarnjaroen W, Chao Y, Yen CJ, Lausoontornsiri W, Chen PJ, Sanpajit T, Camp A, Cox DS, Gagnon RC, Liu Y, Raffensperger KE, Kulkarni DA, Kallender H, Ottesen LH, Poon RTP, Bottaro DP.
A Phase I/II Multicenter Study of Single-Agent Foretinib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma.
Clin Cancer Res 2017; 23(10):2405-2413.
[Citation: 30] [IF: 10.20 (JCR 2017)]
Lam KO, Lee KC, Chiu J, Lee VH, Leung R, Choy TS, Yau T.
The real-world use of regorafenib for metastatic colorectal cancer: multicentre analysis of treatment pattern and outcomes in Hong Kong.
Postgrad Med J 2017; 93(1101):395-400.
[Citation: 14 ] [IF: 2.08 (JCR 2017)]
Ng L, Wan TM, Man JH, Chow AK, Iyer D, Chen G, Yau TC, Lo OS, Foo DC, Poon JT, Leung WK, Pang RW, Law WL.
Identification of serum miR-139-3p as a non-invasive biomarker for colorectal cancer.
Oncotarget 2017; 8(16):27393-27400.
[Citation: 40 ] [IF: 5.17 (JCR 2016)]
El-Khoueiry AB*, Sangro B*,Yau T , Crocenzi TS, Kudo M, Hsu C, Kim TY, Choo SP, Trojan J, Welling THRd Meyer T, Kang YK, Yeo W, Chopra A,erson J, Dela Cruz C, Lang L, Neely J, Tang H, Dastani HB, Melero I.
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.
The Lancet 2017; 389(10088):2492-2502.
[Citation: 2062 ] [IF: 53.25 (JCR 2017)]
Miguel Martin , Frankie A Holmes, Bent Ejlertsen, Suzette Delaloge , Beverly Moy, Hiroji Iwata , Gunter von Minckwitz , Stephen K L Chia , Janine Mansi , Carlos H Barrios , Michael Gnant , Zorica Tomašević , Neelima Denduluri , Robert Šeparović , Erhan Gokmen , Anna Bashford , Manuel Ruiz Borrego , Sung-Bae Kim , Erik Hugger Jakobsen , Audrone Ciceniene , Kenichi Inoue , Friedrich Overkamp , Joan B Heijns , Anne C Armstrong , John S Link , Anil Abraham Joy , Richard Bryce , Alvin Wong , Susan Moran , Bin Yao, Feng Xu , Alan Auerbach , Marc Buyse , Arlene Chan , ExteNET Study Group
Neratinib After Trastuzumab-Based Adjuvant Therapy in HER2-positive Breast Cancer (ExteNET): 5-year Analysis of a Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial.
Lancet Oncology 2017 Dec;18(12):1688-1700
[Citation: 372 ] [IF: 36.42 (JCR 2017)]
Chiu JW, Kwok G, Yau T, Leung R.
Editorial to “Palbociclib and letrozole in advanced breast cancer”.
Transl Cancer Res 2017; 6(0):S376-S379
[Citation: 3 ] [IF: 1.20 (JCR 2017)]
Kwok GW, Leung RC-Y, Chiu J, Tang V, Yau TC.
A phase II study of capecitabine, oxaliplatin and irinotecan (XELOXIRI) as salvage therapy in patients with refractory metastatic colorectal cancer.
Journal of Clinical Oncology. 2017;35(15_suppl):e15049-e.
[Citation: - ] [IF: 26.36 (JCR 2017)]